II
ELDN icon

Inspire Investing’s Eledon Pharmaceuticals ELDN Stock Holding History

Inspire Investing’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-194,688
Closed -$802K – 826
2024
Q4 		$802K Buy
+194,688
New +$768K 0.09% 270

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Inspire Investing's ELDN Position: Q1 2025 in Review

Inspire Investing sold out of Eledon Pharmaceuticals (ELDN) in Q1 2025, closing a stake of 194,688 shares — an estimated $802K sold.

Inspire Investing first reported a position in ELDN in Q4 2024 and held it in 1 quarter. The position peaked at $802K in Q4 2024. 83 funds tracked by Wall St. Rank hold ELDN as of Q1 2025.

  • Inspire Investing reported no remaining Eledon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Inspire Investing sold 194,688 Eledon Pharmaceuticals shares in Q1 2025, an estimated $802K.
  • Inspire Investing first reported a position in Eledon Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Inspire Investing's Eledon Pharmaceuticals position peaked at $802K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2025.

Based on Inspire Investing's 13F filing for Q1 2025, filed 3 Jun 2025.